Abstract:

Objective    To explore the improvement of lung function and airway inflammation by using glucocorticoid and long-acting β2-agonists (CABA)or by using a single drug for chronic obstructive pulmonary disease(COPD). Methods    60 moderate COPD patients were randomly divided  into four groups: the treatment group 1 inhaled shamoteluo / fluticasone and formoteroln, the treatment group 2 inhaled formoterol, the treatment group 3 inhaled budesonide, and the control group used ammonia Tualkali and short-acting β2 receptor agonists on-demand applications. Blood gas analysis, FEV1.0%, serum tumor necrosis factor (TNF-α) and transforming growth factor (TGF-β) were determined before the treatment and at 3, 6, 12, 24 months during the treatment. Results    Acute attacks in the treatment groups were significantly reduced. Compared with the control group there were significant differences (P<0.05), and in the treatment group 1, the difference was the most significant (P<0.01). At 6 months, FEV1.0%, TGF-β, and TNF-α had more significant differences in the treatment groups than in the control group (P<0.05), but there were no significant difference between the  24 months  group and the 12 months(P> 0.05), while there were no significant changes both before and after the treatment in the treatment groups (P> 0.05). PaO2 of the four groups had no significant changes from that before the treatment (P>0.05). Conclusion     Inhalation of both longterm glucocorticoid and LABA, or single glucocorticoids or single LABA can reduce acute attacks of COPD, improves patients‘ lung functions, and reduces concentrations of serum TGF-β and TNF-α. The effect of inhaled glucocorticoid in combination with LABA is more valuable than single inhalation of glucocorticoids or LABA.

Key words: Pulmonary disease， chronic obstructive; Glucocorticoids; Long-acting β2-agonists; Airway inflammation